In cancer cells, NRF2 activation often leads to increased expression of anti-apoptotic proteins such as B-cell lymphoma 2 (Bcl-2) and Bcl-2-like protein 1 (Bcl-xL), which contributes to enhanced cell survival and drug resistance [104,105]. This evidence concerns the gene BCL2L1 and cancer.